DENTSPLY SIRONA Competitors

Align Technology (NASDAQ:ALGN) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Volatility & Risk

Align Technology has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.

Earnings and Valuation

This table compares Align Technology and DENTSPLY SIRONA's gross revenue, earnings per share (EPS) and valuation.

Align Technology has higher earnings, but lower revenue than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Align Technology and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Institutional & Insider Ownership

86.4% of Align Technology shares are held by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are held by institutional investors. 1.2% of Align Technology shares are held by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Align Technology and DENTSPLY SIRONA, as provided by MarketBeat.com.

Align Technology presently has a consensus target price of $287.00, suggesting a potential downside of 14.23%. DENTSPLY SIRONA has a consensus target price of $49.4286, suggesting a potential upside of 10.57%. Given DENTSPLY SIRONA's stronger consensus rating and higher possible upside, analysts clearly believe DENTSPLY SIRONA is more favorable than Align Technology.

Summary

Align Technology beats DENTSPLY SIRONA on 9 of the 13 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Risk & Volatility

West Pharmaceutical Services has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Dividends

West Pharmaceutical Services pays an annual dividend of $0.64 per share and has a dividend yield of 0.2%. DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 0.9%. West Pharmaceutical Services pays out 19.8% of its earnings in the form of a dividend. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. West Pharmaceutical Services has raised its dividend for 24 consecutive years and DENTSPLY SIRONA has raised its dividend for 1 consecutive years. DENTSPLY SIRONA is clearly the better dividend stock, given its higher yield and lower payout ratio.

Earnings and Valuation

This table compares West Pharmaceutical Services and DENTSPLY SIRONA's top-line revenue, earnings per share (EPS) and valuation.

DENTSPLY SIRONA has higher revenue and earnings than West Pharmaceutical Services. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares West Pharmaceutical Services and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Insider and Institutional Ownership

92.6% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 1.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for West Pharmaceutical Services and DENTSPLY SIRONA, as provided by MarketBeat.com.

West Pharmaceutical Services presently has a consensus target price of $286.6667, suggesting a potential downside of 0.11%. DENTSPLY SIRONA has a consensus target price of $49.4286, suggesting a potential upside of 10.57%. Given DENTSPLY SIRONA's higher possible upside, analysts clearly believe DENTSPLY SIRONA is more favorable than West Pharmaceutical Services.

Summary

West Pharmaceutical Services beats DENTSPLY SIRONA on 10 of the 17 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Cooper Companies (NYSE:COO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Volatility & Risk

DENTSPLY SIRONA has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Cooper Companies has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for DENTSPLY SIRONA and Cooper Companies, as provided by MarketBeat.

DENTSPLY SIRONA presently has a consensus target price of $49.4286, indicating a potential upside of 10.57%. Cooper Companies has a consensus target price of $339.9167, indicating a potential downside of 2.17%. Given DENTSPLY SIRONA's higher possible upside, research analysts clearly believe DENTSPLY SIRONA is more favorable than Cooper Companies.

Valuation & Earnings

This table compares DENTSPLY SIRONA and Cooper Companies' gross revenue, earnings per share (EPS) and valuation.

Cooper Companies has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DENTSPLY SIRONA and Cooper Companies' net margins, return on equity and return on assets.

Dividends

DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 0.9%. Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. Cooper Companies pays out 0.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. DENTSPLY SIRONA has raised its dividend for 1 consecutive years and Cooper Companies has raised its dividend for 1 consecutive years.

Insider and Institutional Ownership

96.0% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 88.8% of Cooper Companies shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by insiders. Comparatively, 1.4% of Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cooper Companies beats DENTSPLY SIRONA on 11 of the 16 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional & Insider Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 87.7% of Quidel shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 14.1% of Quidel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for DENTSPLY SIRONA and Quidel, as provided by MarketBeat.

DENTSPLY SIRONA presently has a consensus target price of $49.4286, indicating a potential upside of 10.57%. Quidel has a consensus target price of $189.6667, indicating a potential downside of 23.98%. Given DENTSPLY SIRONA's stronger consensus rating and higher possible upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Quidel.

Earnings and Valuation

This table compares DENTSPLY SIRONA and Quidel's revenue, earnings per share (EPS) and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Quidel. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DENTSPLY SIRONA and Quidel's net margins, return on equity and return on assets.

Volatility and Risk

DENTSPLY SIRONA has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.

Summary

Quidel beats DENTSPLY SIRONA on 7 of the 13 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional & Insider Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 96.3% of Haemonetics shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for DENTSPLY SIRONA and Haemonetics, as provided by MarketBeat.

DENTSPLY SIRONA presently has a consensus target price of $49.4286, indicating a potential upside of 10.57%. Haemonetics has a consensus target price of $117.50, indicating a potential upside of 24.40%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts plainly believe Haemonetics is more favorable than DENTSPLY SIRONA.

Earnings and Valuation

This table compares DENTSPLY SIRONA and Haemonetics' revenue, earnings per share (EPS) and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Haemonetics. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DENTSPLY SIRONA and Haemonetics' net margins, return on equity and return on assets.

Volatility and Risk

DENTSPLY SIRONA has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Summary

Haemonetics beats DENTSPLY SIRONA on 10 of the 14 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and ICU Medical (NASDAQ:ICUI) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional & Insider Ownership

96.0% of DENTSPLY SIRONA shares are owned by institutional investors. Comparatively, 92.4% of ICU Medical shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Comparatively, 10.9% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for DENTSPLY SIRONA and ICU Medical, as provided by MarketBeat.

DENTSPLY SIRONA presently has a consensus target price of $49.4286, indicating a potential upside of 10.57%. ICU Medical has a consensus target price of $214.00, indicating a potential upside of 12.42%. Given ICU Medical's stronger consensus rating and higher possible upside, analysts plainly believe ICU Medical is more favorable than DENTSPLY SIRONA.

Earnings and Valuation

This table compares DENTSPLY SIRONA and ICU Medical's revenue, earnings per share (EPS) and valuation.

DENTSPLY SIRONA has higher revenue and earnings than ICU Medical. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DENTSPLY SIRONA and ICU Medical's net margins, return on equity and return on assets.

Volatility and Risk

DENTSPLY SIRONA has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.

Summary

ICU Medical beats DENTSPLY SIRONA on 9 of the 14 factors compared between the two stocks.